Price trends of giritinib in 2025: drug prices and market expectations

Gilitinib is a new oral tyrosine kinase inhibitor that mainly targets FLT3 mutations and is particularly suitable for patients with relapsed or refractory acute myeloid leukemia (AML) carrying FLT3-ITD or FLT3-TKD mutations. The drug inhibits the proliferation and survival of leukemia cells by blocking abnormal signaling of FLT3 receptor kinase, thereby delaying disease progression and improving survival. In clinical studies, giritinib has shown significantly better efficacy than traditional chemotherapy, especially after failure of multiple lines of treatment, and still has a significant remission rate. It is considered to be one of the key targeted drugs in the current treatment of FLT3-mutated AML.

In China, the original drug gilitinib has been introduced by Astellas (Astellas) and has been approved for marketing, becoming the first targeted treatment option for FLT3 mutated AML on the domestic market. However, because it is not covered by national medical insurance, patients face a high financial burden. At present, the common specifications in China are 40 mg × 21 tablets × 2 plates (i.e. 42 tablets). Each box sells for about 20,000 yuan, and the monthly cost of a complete treatment cycle may reach more than 40,000 yuan. Due to the high price, some patients choose to purchase more economical alternative versions from overseas. For example, the Hong Kong version of the original drug is usually priced at about 90,000 yuan, while in the European market, the price of a box of 40 mg × 84 tablets of giritinib may even exceed 200,000 yuan, prohibiting most patients.

In order to relieve economic pressure, more and more patients are also paying attention to overseas generic versions of drugs. Taking the Laos version as an example, the specification of the drug is 40 mg × 90 tablets, and the price is only more than 2,000 yuan, less than one-tenth of the price of the original drug. These generic drugs are highly consistent with the original drugs in terms of drug composition and bioavailability, and are highly clinically substitutable, but they still need to be used under the guidance of a doctor. In general, giritinib, as an important breakthrough in the targeted treatment of AML, has brought longer survival and higher remission rates to some patients. However, its high cost and limitations in medical insurance coverage are still real challenges. Rational selection of drug sources and development of individualized treatment plans will be the key to long-term benefit for patients.

Reference materials:https://www.xospata.com/